Last updated: May 28, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06780098 | 2 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | Unknown mechanism |
| NCT06772623 | 1, 2 | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | c-Met -- antibody-drug conjugate (telisotuzumab adizutecan) + PD-1 -- immune checkpoint inhibitors |
| NCT06496659 | — | Segmentectomy After Induction Therapy (SAINT) | Unknown mechanism |
| NCT06788912 | 2 | Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) | PD-1 -- immune checkpoint inhibitor (Pembrolizumab) + chemotherapy + Trop-2 -- antibody-drug conjugate (Sacituzumab tirumotecan) |
| NCT06694454 | 1, 2 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | DNA methyltransferases -- epigenetic inhibitor (azacytidine) + PD-L1 -- immune checkpoint inhibitor (durvalumab) + platinum-based chemotherapy |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 32 |
| Shanghai Pulmonary Hospital, Shanghai, China | 30 |
| Tianjin Medical University Cancer Institute and Hospital | 27 |
| Hunan Province Tumor Hospital | 24 |
| AstraZeneca | 21 |
Countries/regions with the most active trial sites for lung cancer (nsclc). A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 1, 2026 | NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | Indocyanine green -- fluorescent dye for surgical navigation |
| Nov 30, 2026 | NCT07579221 | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer | EZH2 + PRMT5 -- epigenetic enzyme inhibitors |
| Aug 7, 2026 | NCT07012031 | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | KRAS G12C -- covalent inhibitor + HER2 -- antibody-drug conjugate (ADC) |
| Aug 1, 2026 | NCT07436858 | Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer | HER2 -- radiolabeled antibody for PET imaging (diagnostic antibody) |
| Jul 1, 2026 | NCT07495098 | Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer | DNA crosslinking agent -- platinum-based chemotherapy (small molecule) |
| Jul 1, 2026 | NCT07382726 | Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial | KRAS G12C -- covalent inhibitor (Adagrasib); B7-H3 -- antibody-drug conjugate (ADC) (Izalontamab Brengitecan) |
| Jul 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| Jun 2026 | NCT07285148 | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | EGFR -- tyrosine kinase inhibitor (TKI) plus novel agent |
You've seen the lung cancer (nsclc) landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.